Is there an immunologic basis for schizophrenia? (Q40426678)

20 September 2017

Is there an immunologic basis for schizophrenia? (English)

1 reference

20 September 2017

0 references

Brian E Leonard

1

1 reference

20 September 2017

1 May 2005

1 reference

Expert Review of Clinical Immunology

20 September 2017

1 reference

20 September 2017

1

1 reference

20 September 2017

1

1 reference

20 September 2017

103-112

1 reference

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

20 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

A decrease of reelin expression as a putative vulnerability factor in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ gamma/delta+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Immunoregulators in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Interleukin-6 stimulates anterior pituitary hormone release in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Immunological dysfunction in schizophrenia: a systematic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Microglia: Intrinsic immuneffector cell of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Immunologic and Coagulation Disorders in Chlorpromazine-Treated Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Clinical and laboratory evidence of autoimmunity in acute schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Autoantibodies against 60-kDa heat shock protein in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Antinuclear autoantibodies in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Molecular mimicry and the pathogenesis of insulin-dependent diabetes mellitus: still just an attractive hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

COX-2 inhibitors as adjunctive therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Prostaglandins as modulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Localization of interleukin 1 type I receptor mRNA in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Autoimmune diseases in the pedigrees of schizophrenic and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

Cytokine profiles in drug-naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.1.1.103

21 January 2018

Identifiers

DOI

10.1586/1744666X.1.1.103

1 reference

20 September 2017

1 reference

PubMed ID

20477658